Because there is almost no study on the effects of ghrelin in AD-related sleep–wake disorders, further well-controlled clinical trials regarding the positive effects of ghrelin on disruption in the circadian rhythm and quality of life in patients with AD are needed. This evidence concerns the gene GHRL and Alzheimer disease.